pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,603 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT821Endpoints617BioPharma Dive237onclive165BioSpace86Fierce Biotech85raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6Hematology
  • STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
    The E.U. reached a provisional deal to strengthen the supply of essential medicines and avoid shortages by ‌boosting domestic production and reducing reliance on imports.
    STAT · 2mo ago↗ source
  • EU reaches provisional deal on Critical Medicines Act
    The Critical Medicines Act reached its next milestone on Tuesday, after the European Parliament and the Council provisionally voted it through. The proposed regulation aims to improve the European…
    Endpoints · 2mo ago↗ source
  • STAT+: Makary departs FDA amid turmoil as Diamantas, agency’s top food official, steps in
    Food and Drug Administration Commissioner Marty Makary is resigning from his role after a tumultuous tenure.
← prev
page 47 of 65
next →
21
fda recalls20
fda medwatch16
6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 2mo ago
↗ source
  • FDA Commissioner Makary resigns
    FDA Commissioner Marty Makary has resigned after his job status hung in the balance for days. President Donald Trump confirmed the news Tuesday in a social media post. Makary’s decision centered ...
    Endpoints · 2mo ago↗ source
  • Iran war disruptions begin to emerge upstream of the pharma supply chain
    As the Iran war enters its third month, its knock-on effects on raw materials, energy costs and shipping are beginning to be felt in the pharma industry. While the Middle East is barely a player ...
    Endpoints · 2mo ago↗ source
  • What I learned at a journalism fellowship about covering healthcare AI
    Last week, I was reminded that reporting on AI in healthcare requires continuous scrutiny of the incentives that drive it. Thanks to a fellowship hosted by SABEW, in partnership with ...
    Endpoints · 2mo ago↗ source
  • Supreme Court extends mifepristone deadline
    The deadliest drug in the country, the new name for PCOS, and more health news from Morning Rounds
    STAT · 2mo ago↗ source
  • STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’
    In this edition of STAT Health Tech: Hims earnings, Omada's PBM strategy, and the uphill battle faced by new sepsis algorithms.
    STAT · 2mo ago↗ source
  • STAT+: Hims’ sales miss as telehealth competition grows
    Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
    A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.
    onclive · 2mo ago↗ source
  • FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma
    Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.
    onclive · 2mo ago↗ source
  • Five burning Qs for Isomorphic Labs after $2.1B raise for AI biotech
    Isomorphic Labs said Tuesday it had closed a $2.1 billion Series B round, cementing its bellwether role in using AI for drug discovery. For privately held companies, Isomorphic’s raise is the secon…
    Endpoints · 2mo ago↗ source
  • [177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC
    [177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.
    onclive · 2mo ago↗ source
  • Pfizer and Arvinas give disappointing breast cancer drug to Rigel
    Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. T…
    Endpoints · 2mo ago↗ source
  • FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma
    The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.
    onclive · 2mo ago↗ source
  • STAT+: STAT examines America’s deadliest drug
    STAT examines America's failure to address excessive alcohol use across decades.
    STAT · 2mo ago↗ source
  • Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
    Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill Anderson. “We’re going to be careful, but also aggressive,” Anderson said on a first-qu…
    Endpoints · 2mo ago↗ source
  • Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
    Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
    The 17 pharmaceutical companies anchoring TrumpRx poured more than $130 million into federal lobbying in 2025 — a nearly 23% surge
    STAT · 2mo ago↗ source
  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 2mo ago↗ source
  • Knit Health raises $11.6M for 'fundamentally different' approach to healthcare AI
    A startup that spun out of UC Berkeley aims to improve healthcare operations by getting AI to think like a doctor would. Knit Health launched with $11.6 million in seed funding co-led by Uncork Cap…
    Endpoints · 2mo ago↗ source
  • Unmet Needs in Endometrial Cancer
    Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.
    onclive · 2mo ago↗ source
  • EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs
    In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that…
    onclive · 2mo ago↗ source
  • Future Directions in Relapsed and Refractory Multiple Myeloma
    onclive · 2mo ago↗ source
  • Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer
    Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas.
    onclive · 2mo ago↗ source